From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease
Variable | Details and levels simulated |
---|---|
Vaccination: infant cohort (EPI cohort) | 6, 10, 14 weeks; booster at 21 months |
Vaccination: children cohort (5–17 months cohort) | Ages between 5–17 months first dose, and for 3rd dose 8–20 months; booster at 26–38 months |
Model variants [8] | 1. R0000 Base model 2. R0068 Heterogeneity in transmission: within-host variability 3. R0131 Immunity decay in effective cumulative exposure 4. R0132 Immunity decay in immune proxies 5. R0133 Immunity decay in both immune proxies and effective cumulative exposure 6. R0670 Heterogeneity in susceptibility to co-morbidity |
EIR | 0.1a, 1, 2, 4, 8, 16, 64, 256 |
Access to uncomplicated case management (%)b | 0, 5, 40 |
Access inpatient care for severe cases (%)c | 0, 100 |
Vaccination coveraged | 0, 100 |
Initial efficacy against infection of third dose (%) | 30, 60, 80, 100 |
Half-life (years) | 0.5, 1, 3, 5 |
Initial efficacy against infection of boosting dose (%)e | Third dose efficacy, 30, 100 |
Weibull decay shape parameter (k) | k = 1 (exponential) k = 0.5 (bi-phasic, quick decay followed by slow decay) k = 3 (slow decay, followed by quick decay) |